Breaking News


Use of biological agents in psoriatic disease: An Italian perspective


A flexible framework for the use of biological agents in psoriatic disorders (PD) was compiled by a group of 5 Italian dermatologists and 6 rheumatologists. The guidelines were based on published studies and clinical opinion. The three key tumor necrosis factor-alpha (TNF-alpha) inhibitors were adalimumab, etanercept and infliximab and were all deemed effective in PD. They were recommended for use in moderate-severe disease refractory to systemic therapy with nonbiological agents. Data from phase II-III randomized controlled trials for other biological agents were also discussed, including golimumab, ustekinumab, ABR-874 and alefacept. Definitions of moderate-severe PD based on the Psoriasis Area and Severity Index, body surface area affected and the Dermatology Life Quality Index ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list